Who Paid My Doc
Alain Taylon
Endocrinology, Diabetes & Metabolism Omaha, NE Medical Doctor
NPI 1710023866 CMS profile 32010
7710 Mercy Rd Ste 426, Omaha, NE 68124
General payments
$4,451
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$2,750
Through program year 2023, Alain Taylon of Omaha, NE is reported in the CMS Open Payments database as having received $4,451 across 411 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,750 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 66th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $143 | 8 | |
| 2022 | General | $531 | 49 | |
| 2021 | General | $751 | 78 | |
| 2020 | General | $971 | 85 | |
| 2019 | General | $2,055 | 191 |
Beside peers
- Alain Taylon
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Alain Taylon were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Alain Taylon | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,055 | $494 | $123–$2,253 | $163 |
| 2020 | $971 | $335 | $85–$1,841 | $114 |
| 2021 | $751 | $398 | $88–$1,981 | $132 |
| 2022 | $531 | $364 | $88–$1,568 | $149 |
| 2023 | $143 | $420 | $113–$1,614 | $160 |
| 2024 | $0 | $440 | $121–$1,646 | $164 |
| 2025 | $0 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
108
Drug cost
$2,378
Branded share of claims
10.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | Brand | 11 | $1,116 | |
| Rosuvastatin Calcium | Generic | 15 | $534 | |
| Levothyroxine Sodium | Generic | 23 | $237 | |
| Glimepiride | Generic | 22 | $175 | |
| Atorvastatin Calcium | Generic | 11 | $174 | |
| Metformin Hcl | Generic | 26 | $144 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
411 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Nebraska
Marium Ilahi
Endocrinology, Diabetes & Metabolism · Omaha, NE
Cyrus Desouza
Endocrinology, Diabetes & Metabolism · Omaha, NE
Shannon Wakeley
Endocrinology, Diabetes & Metabolism · Lincoln, NE
Timothy Wahl
Endocrinology, Diabetes & Metabolism · Omaha, NE
Leslie Eiland
Endocrinology, Diabetes & Metabolism · Omaha, NE
Anupam Kotwal
Endocrinology, Diabetes & Metabolism · Omaha, NE
Related records
Endocrinology, Diabetes & Metabolism in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.